Decreased sirtuin 1 in type 2 diabetes patients with abnormal BMD

Area of Science:

• Endocrinology
• Metabolic Disorders
• Bone Biology

Background:

• Sirtuin 1 (SIRT1) is implicated in diabetes mellitus and bone metabolism.
• Its precise role in bone mineral density (BMD) and bone metabolism in type 2 diabetes mellitus (T2DM) requires further elucidation.

Purpose of the Study:

• To investigate the association between SIRT1 levels, BMD, and bone metabolism in newly diagnosed T2DM patients.
• To examine alterations in SIRT1 levels in T2DM patients with concurrent osteoporosis or osteopenia.

Main Methods:

• Serum SIRT1 levels and bone turnover markers (osteocalcin, P1NP, β-CTX) were measured in 69 T2DM patients and 82 controls.
• BMD was assessed using DXA; patients were subgrouped by BMD status.
• Risk factors for osteoporosis/osteopenia in T2DM were evaluated.

Main Results:

• T2DM patients exhibited significantly lower serum SIRT1 levels compared to controls.
• Osteoporosis incidence was higher in T2DM patients (34.8% vs. 18.3%).
• T2DM patients with osteoporosis/osteopenia had significantly reduced SIRT1 levels compared to those with normal BMD.

Conclusions:

• Decreased serum SIRT1 levels correlate with bone turnover markers in T2DM.
• SIRT1 may serve as an independent risk factor and a potential biomarker for bone metabolism disorders in T2DM patients.